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SUMMARY 
Thyroid carcinomas is not the most common canine neoplasm, but since it is more common 
than the benign thyroid adenoma it is still an important disease to recognize. Most commonly 
it affects older dogs, with a mean age of about 10 years. No predilection for gender is seen, but 
it seems to be more common in certain breeds like Golden retriever, Beagle and Boxer.  
The etiology of thyroid carcinomas is still unknown. There are several theories, but no proven 
facts. This makes it difficult to treat the condition medically, as we are not sure what to direct 
the treatment at. The most successful treatment seems to be surgery, surgery combined with 
chemotherapy or surgery combined with external radiation therapy. There are a few studies on 
the subject which do not all agree with each other. They do however all agree that treatment 
improves survival time.  
The most common clinical sign of thyroid carcinoma is a lump in the ventral throat region. 
Dyspnea, difficulties to swallow, cough or signs of hyper-/hypothyroidism are other reported 
symptoms.  
Small studies on thyroid carcinoma and the outcome of treatment have been published abroad, 
but none on the dogs treated at the Swedish University Animal Hospital in Uppsala (UDS). The 
aim of this study was therefore to increase the knowledge of thyroid carcinomas by writing a 
literature review, and also to investigate the prognosis of treatment by comparing different 
treatment methods with no treatment. In addition, the study also investigated methods of 
diagnosis and tried to identify factors which increase/decrease survival time. The foremost goal 
was to give veterinarian clinicians more information about the diagnosis, ways of treatment and 
the prognosis of thyroid carcinomas. The hypothesis was that treatment (surgical, medical 
and/or radiation) increased survival time in dogs diagnosed with thyroid carcinomas.  
In agreement with previous studies, both groups of treated dogs showed a longer survival time 
than the dogs not treated. However, this difference could not be shown to be statistically 
significant. As for the factors increasing/decreasing survival time, the only significant result 
was that neoplastic ectopic thyroid tissue decreased survival time. All other analyzed factors 
such as clinical attachment to underlying tissue, presence of metastasis, tumor volume and 
hyperthyroid VS euthyroid dog showed a logical trend, but had no statistically significant 
impact. Further research on bigger study populations need to be performed to decide if these 
factors affect the survival time. The survival analysis for grade of tumor did not show a logical 
result. FNA biopsy was proved to provide a conclusive diagnosis in significantly less cases than 
tissue biopsy.    
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Thyroid carcinomas are not the most common neoplastic diagnosis in dogs, only 1-2% are 
affected. (Brodery & Kelly, 1968; Wucherer & Wilkes, 2010). However, it is more often 
reported than the benign thyroid neoplasm; thyroid adenoma. In dogs, carcinomas make up for 
90% of thyroid neoplasms detected during life (Wucherer & Wilkes, 2010). Usually, only one 
of the thyroid lobes is affected (Taeymans et al., 2013; Deitz et al., 2014). 
The etiology of thyroid tumors in dogs remains unknown. In humans, scientists have found that 
extensive external radiation to the cervical region in young age is linked to the development of 
thyroid neoplasms (Ron et al., 1995). Internal radiation alone (examination with 131I for 
diagnostic purposes) does not propose an increased risk for developing thyroid neoplasms in 
adulthood (Dickman et al., 2003). The hypothesis is that in papillary carcinoma tyrosine 
receptor kinases like RET and TRK are activated; in follicular carcinoma activating mutations 
in RAS are common to find, and in anaplastic carcinomas inactivation of p53 is common 
(Kondo et al. 2006). As the growth factor for follicular cells is TSH, the hormones binding to 
the TSH-receptor are well studied in thyroid neoplasms. It seems to be able to bind to the TSH-
receptors on the tumor-cells to the same extent as in normal thyroid tissue (Verschueren et al., 
1991). A study from 1996 shows that TSH can stimulate excess release of VEGF (vascular 
endothelial growth factor) in a thyroid neoplasm. VEGF is secreted by some tumor cells to 
increase the blood supply to the tumor and hence, make it grow (Soh et al., 1996). This could 
explain why most thyroid tumors are found to be rich in blood supply (Mitchell et al., 1979).  
In several studies the breeds Boxer, Beagle and Golden Retriever seem to be predisposed for 
thyroid carcinomas. No statistical significance in sex-predilection has been proven, but it is 
more common in elderly dogs with a mean age of about 10 years (Brodery & Kelly, 1968; Leav 
et al., 1976). A fairly recent study by Wurcherer & Wilkes (2010) showed that Golden retrievers 
and Beagles were more predisposed than Boxers. Neither this study showed a sex-predilection, 
but the results revealed an older age of between 10-15 years at discovery of the thyroid 
carcinoma. 
This study will mainly focus on the outcome of treatment in 18 dogs treated for thyroid 
carcinomas at the veterinary university hospital in Uppsala, Sweden. The dogs were divided 
into three groups; not treated, surgical treatment only, and treated both with surgery and 
chemotherapy. They were then compared for survival time using a Kaplan Meier curve. 
Metastatic spread, attachment to underlying tissue, hyperthyroidism and grade 1 VS grade 2 
tumor was also analyzed as potential prognostic factors. Potential predilection factors like sex, 
age and breed was also compared to previous research.  
The aim of this study is to increase the knowledge of thyroid carcinomas by writing a literature 
review, and also investigate the prognosis of treatment by comparing different treatment 
methods with no treatment. In addition to this, the study also investigates methods of diagnosis 
and try to identify factors increasing/decreasing survival time. The goal is to give veterinarian 
clinicians more information about the diagnosis, ways of treatment and the prognosis of thyroid 
carcinomas. The hypothesis is that treatment (surgical, medical and/or radiation) increases 





The thyroid is the largest organ that functions exclusively as an endocrine gland. In dogs it 
consists of two lobes, one on each side of the cranial part of the trachea. The right lobe is 
situated slightly cranial to the left lobe (Zachary & McGavin, 2012).  
Accessory thyroid glands are usually located close to the main organ, but can also be found 
around the hyoid apparatus, along the trachea, in the mediastinum and/or adjacent to the aorta 
(Konig & Liebich, 2014; Swartz et al., 1911). 
Blood is mainly supplied from the common carotid artery branching into the cranial thyroid 
artery, and the caudal thyroid artery. Venous drainage goes through the cranial and middle 
thyroid veins which drain into the internal jugular vein. Lymph drains to the deep cervical 
lymph nodes or directly to the tracheal trunk. Adjacent nerves are the cranial and caudal 
laryngeal nerves, as well as the sympathetic nerve fibers which originate from the cranial 
cervical ganglion (Konig & Liebish, 2014). 
Histology  
Microscopically a normal thyroid gland consists of follicles in varying sizes. These follicles 
contain colloid produced by the follicular cells (epithelial cells) surrounding them. The cells 
are cuboidal to columnar in shape. The secretory pole of the cells is positioned towards the 
lumen of the follicle. Interfollicular and intrafollicular capillaries supply the follicular cells with 
blood.  
The thyroid gland also contains C-cells, or parafollicular cells, which are responsible for the 
secretion of calcitonin. C-cells are found either in the follicular wall or between the follicular 
cells. They do not secret calcitonin to the follicular lumen but directly to the blood through the 
interfollicular capillaries. C-cells contain numerous cytoplasmic secretory granules that are 
immunoreactive for calcitonin.  
As the thyroid gland must produce large amounts of protein hormones, the follicular cells 
contain large amounts of RER (rough endoplasmic reticulum) and have a substantial golgi 
apparatus for packaging of these hormones (Zachary & McGavin, 2012). 
Physiology  
The hypothalamus releases TRH (thyroid releasing hormone) which activates the secretory 
cells, called basophils, in the pars distalis of the adenohypophysis. These cells produce and 
release TSH (thyroid stimulating hormone) (Zachary & McGavin, 2012). 
When TSH binds to the cells of the thyroid gland it releases T3 (tri-iodothyronine) and T4 
(thyroxine), two hormones that control metabolic rate, growth, body temperature, carbohydrate 
metabolism and calcium blood levels (Konig & Liebish, 2014). 
Thyroglobulin is a precursor to T3 and T4, and it is produced in the thyroid gland by the 
follicular cells. It is then transported over the cell membrane to the follicular lumen where it is 
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assembled into T3 and T4. When there is a high concentration of T3 and T4 in the blood 
circulation the hormones act as a negative feedback mechanism on the hypothalamus and 
adenohypophysis. This results in less TRH and TSH production, decreasing the amount of T3 
and T4 being released from the thyroid gland (Zachary & McGavin, 2012). 
C-cells secrete calcitonin when the serum concentration of calcium is too high. When lowered 
the secretion ceases. Calcitonin works by interacting with target cells in the kidneys and bone, 
making the osteoclasts in bone more inactive, and the renal tubules to reabsorb less calcium, 
see figure 1 (Kallio et al., 1972; Cochran et al., 1970). 
 
Figure 1. Description of calcium metabolism. Source of picture: 
http://www2.csudh.edu/nsturm/CHE452/20_Calcium%20Homeostasis16.htm  
Classification of Thyroid carcinomas 
Neoplasms arising from follicular cell-types are divided into follicular-, compact-, papillary- or 
anaplastic thyroid carcinomas. The other type; medullary carcinoma, derives from C-cells. In 
order to test whether the tumor is of follicular- or C-cell origin, immunohistochemistry is used 
by raising antibodies against thyroglobulin and calcitonin. If the cells are positive for 
thyroglobulin, the neoplasm is derived from follicular cells, if the cells are positive for 
calcitonin, the neoplasm is derived from C-cells (Leblanc et al., 1991; Ramos-Vara et al., 2002).  
Ramos-Vara et al., (2002) found another way to determine if the tumor was of thyroid tissue 
origin by using a protein called Thyroid Transcription Factor-1 (TTF-1). TTF-1 was only found 
in thyroid and lung tissue. However, this protein was both a less sensitive and less specific 
marker than thyroglobulin and calcitonin. In combination with thyroglobulin, TTF-1 increased 
the sensitivity for finding follicular thyroid carcinomas though. Leblanc et al. (1991) also 
investigated alternative markers for identifying and classifying thyroid carcinomas. They found 
that the calcitonin-gene-related peptide (CGRP) was even more sensitive than calcitonin in 
finding medullary carcinomas. 
In a study by Leav et al. (1976) the authors divided the carcinomas from 97 dogs into seven 
groups based on macroscopical and microscopical appearance. The classification was based on 




The follicular carcinomas are amongst the more common types of thyroid carcinoma in the dog. 
Fifteen of the 97 dogs in a study by Leav et al. (1976) had a follicular carcinoma, making it the 
third most common malignant thyroid neoplasm in that study. They typically had a firm nodular 
external surface with softer parts focally. The inner core was irregular and contained a soft, 
dark-red caseous material surrounded by firm cream-colored tissue. Hard, gritty spicules are 
recorded to be common in and around the soft central regions. Metastatic foci sometimes lacked 
these spicules (Leav et al., 1976; Leblanc et al., 1991). 
Microscopically the neoplastic cells formed follicles, although a minor part may have contained 
compact tissue. Both micro- and macrofollicular patterns could be observed. Foamy, vacuolated 
colloid was found in the lumen of larger neoplastic follicles but not in the microfollicles. The 
uptake of radioiodine was most profound in the follicular parts of the neoplasm and less in the 
compact areas (Leav et al., 1976; Leblanc et al., 1991). 
In humans the follicular carcinomas seem to be more uncommon. Only 2 of 80 patients had 
follicular carcinomas in a study by Russel et al. (1963). 
Compact cellular carcinomas 
The external texture of compact cellular carcinomas was firm and smooth. The cut surface was 
described to have a creamy color and a fine lobulation.  
Microscopically compact cellular carcinomas had randomly arranged cells in densely packed 
sheets, divided into lobules by thin strands of connective tissue and small blood vessels. A 
minor follicular component was sometimes present. The staining for immunoreactive calcitonin 
was usually negative, meaning the C-cells were not involved (Leav et al., 1976). A study in 
dogs by Brodery and Kelly (1968) showed the compact thyroid carcinomas were the most 
common type of thyroid carcinomas - 14 out of 22 dogs were affected.   
Mixed follicular-compact cellular carcinomas 
Mixed follicular-compact cellular carcinomas were considered to be the most common thyroid 
carcinoma found in the dog (Leav et al., 1976). Up to 58% of dogs with thyroid carcinoma had 
a mixed follicular-compact cellular pattern.  
These neoplasms had a firm surface and an inner core similar to the one found in the follicular 
carcinoma. Microscopically they contained both the follicular carcinoma and compact cellular 
carcinoma. Connective tissue in cribiform patterns separated the follicular and compact cellular 
regions (Leav et al., 1976; Leblanc et al., 1991).  
Mixed papillary-follicular carcinoma 
Mixed papillary-follicular carcinoma was described to be very unusual in dogs. Only one of the 




Macroscopically these tumors were firm and multi-lobulated. The inside had a creamy color 
and a nodular structure. Microscopically the cell nuclei were pleomorphic and lack polarity. 
Some were vesicular, and sometimes had a prominent nucleoli (Leav et al., 1976). 
Metastases were not found in the study by Leav et al., but invasion of the connective tissue 
capsule surrounding the thyroid gland and vessels was seen. However, histologically, mitoses 
were not present.  
In a study by Russel et al. (1963) mixed papillary-follicular carcinoma was reported to be the 
most common type of thyroid carcinomas in humans.  
Anaplastic thyroid carcinomas 
Anaplastic thyroid carcinomas were according to Thomas and Buckwalter, (1973) relatively 
common in humans - 15-20% of the thyroid carcinomas were anaplastic. In dogs however, this 
type of carcinoma was shown to be rare (Mason & Wells 1929).   
Spindle cell carcinoma 
Only one spindle cell carcinoma was found in the dogs examined by Leav et al. (1976). It had 
a firm surface with a cream-colored, homogenous inner texture. Microscopically most of the 
cells were spindle shaped and arranged in small, poorly defined lobules. Mitotic figures were 
numerous and abnormal. Metastasis to the retropharyngeal lymph node was observed. Follicles 
were rarely seen.  
Giant cell carcinoma 
Two of the dogs in the study by Leav et al. (1976) were diagnosed to have an anaplastic giant 
cell carcinoma in the thyroid gland. They both differed macroscopically and microscopically, 
but were prone to metastasize and invade surrounding tissues, like the sternocephalic muscles, 
carotid sheath, and the lateral surface of the esophagus. One of these tumors contained 
osteosarcomatous parts.  
Diffuse small cell carcinoma 
The diffuse small cell carcinoma was described by Leav et al. (1976) to be a firm neoplasm. It 
was adherent to the esophagus and showed metastasis to the lungs, kidneys, the adrenal gland, 
mesentery and the diaphragm. Only one of the dogs in the referred study was considered to 
have a diffuse small cell carcinoma.  
Microscopically, it consisted of loosely aggregated uniform small, round cells with an oval, 
vesicular nucleus. Mitosis was rare. In a few areas, the small cells might have created structures 
resembling follicles (Leav et al., 1976). 
Aldinger et al. (1978) discussed that small cell carcinoma was in fact a type of lymphoma which 
should not be part of the classification of thyroid carcinomas. A clinicopathologic study 
performed by Rayfield et al. (1971) indicated that even though small cell carcinoma resembled 





Medullary carcinomas, also called C-cell carcinomas, arise from C-cells and in humans they 
are usually associated with excess secretion of calcitonin. Despite the abnormal secretion of 
calcitonin, human patients usually did not show hypocalcemia or hypophosphatemia (Tashjian 
et al., 1974). However, in dogs with medullary carcinoma, hypocalcemia had been observed 
(Leav et al., 1976). 
Both of the medullary carcinomas in the study by Leav et al. (1976) were unilateral and 
involved the right thyroid lobe. Macroscopically, the medullary carcinomas were firm and 
about 4 cm in diameter and had nodular external surfaces. The inside differed between the two 
tumors, but they both showed vascular and capsular invasiveness and were positive in 
immunoperoxidase staining for calcitonin.  
In the study by Leblanc et al. (1991) no mitosis was seen in the canine medullary carcinomas.  
Some studies showed that medullary carcinomas in dogs may be more common than previous 
research studies had shown, as they were easily mistaken for compact follicular carcinomas. In 
order to know for certain, immunoperoxidase staining with calcitonin must be performed (Lee 
et al., 2006; Carver et al., 1995).  
In a recent study medullary carcinomas were found in a family of dogs which implied clinical 
similarity to the familial form of medullary thyroid carcinoma (FMTC) in humans (Lee et al., 
2006). However, the RET-mutation present in 95% of the human cases of FMTC could not be 
confirmed in these dogs. The clinical findings still indicated that some thyroid carcinomas may 
have been hereditary. 
Adenomas 
Leav et al. (1976) also writes about adenomas of the thyroid in canines. Adenomas are the 
benign type of neoplasm in the thyroid, and in contrary to carcinomas they do not metastasize, 
nor grow fast. There are two types of adenomas; follicular and papillary. Clinically adenomas 
are described to be more uncommon in dogs than carcinomas are, but after post-mortem 
examinations it is found to be more common than previously known. About 30% (44 of 141) 
of the dogs with a thyroid neoplasia has an adenoma. Only seven of these are large enough to 
be detected during life. Dogs with adenomas show no evidence of hypo- or hyperthyroidism.  
As this review focuses on carcinomas, adenomas will not be discussed further.  
Ectopic thyroid tumors 
Ectopic thyroid tissue may be found in healthy dogs but similar to the original thyroid gland it 
can become neoplastic. The ectopic thyroid tissue was usually located along the cervical region, 
hyoid region or adjacent to the aorta (Swartz et al., 1911).  
Aortic body carcinoma and ectopic thyroid carcinoma can arise from the same location in the 
thoracic cavity. They are similar in that both are vascular, invasive and have tendencies to grow 
within lymphatics. Even histologically they are fairly similar (Cheville, 1972). Leav et al. 
(1976) differed the two tumors by looking for follicles, or structures similar to follicles which 
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were found in most ectopic thyroid tumors. He also studied the cells closely, the cells in aortic 
body carcinomas differed more in size and shape than did the cells in ectopic thyroid 
carcinomas. Also, PAS-staining droplets are found in ectopic thyroid carcinomas, and an 
argyrophilic network of fibers surrounding nests of cells is noted in aortic body carcinomas, but 
not in the ectopic thyroid carcinomas. 
Staging of thyroid neoplasms 
In one review from 2000, the scientists suggest that all use one staging system to make the 
staging easier. They suggest the TNM-staging, (tumor, lymph nodes and metastases), (table 1-
4) as it considers several factors, works for all types of thyroid neoplasms and is universally 
available (Brierley et al., 2000). 
Table 1. T; primary tumor  
Stage Size 
T0 No evidence of tumor 
(microscopic residual disease)  
T1 <2 cm 
T2 2-5 cm 
T3 >5 cm 
Substage a Freely movable tumor 
Substage b Tumor fixed to surrounding 
tissue 
 
Table 2. N; regional lymph nodes 
N0 No evidence of lymph node 
involvement 
N1 Ipsilateral lymph node 
involvement 
N2 Bilateral lymph node 
involvement 
Substage a Lymph node freely movable 
Substage b Lymph node fixed 
 
Table 3. Metastases 
M0 No evidence of distant 
metastasis 
M1 Distant metastasis detected 
Owen, 1980. TNM classification of tumors in domestic animals, Geneva, World Health organization.  
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Table 4. Staging 
Stage Primary tumor Regional lymph nodes Distant metastases 
1 T1 a, b N0 M0 
2 T0 N1 M0 
 T1 a, b N1 M0 
 T2 a, b N0 or N1 a M0 
3 T3 Any N M0 
 Any T N1 b or N2 b M0 
4 Any T Any N M1 
Owen, 1980. TNM classification of tumors in domestic animals, Geneva, World Health organization.  
Clinical signs 
Several articles describes clinical symptoms of thyroid carcinomas. In table 5 there is a 
compilation of the most common symptoms reported in dogs with thyroid carcinoma.  
Table 5. Clinical signs of thyroid carcinomas 
Study Swelling in 
ventral 
throat region 
Coughing Dyspnea Dysphonia Edema 
R.S Brodey et 
al. 
+  +  + 
I. Leav et al. +  +   
J.R Carver et 
al. 
+ + + +  
J. Harari et al. + + +   
O. Taeymans 
et al. 
+  + +  
K. Deitz et al. + +    
 
As stated from table 5, a swelling in the ventral throat region and dyspnea are the most common 
symptoms, but also coughing, edema, dysphonia and dysphagia occurs. Clinical movability of 
the mass does not seem to correlate with malignancy or type of tumor (Deitz et al., 2014). 
Another characteristics of thyroid carcinomas in dogs may be signs of hypo- or 
hyperthyroidism. These carcinomas are in veterinary medicine called functional thyroid 
carcinomas and can consist of either ectopic thyroid tissue or origin thyroid tissue (Deitz et al., 
2014). In a case report, symptoms like weight loss, increased heart rate, hyperactivity, anxiety 
and excessive panting are described, as well as a swelling in the throat region. The dog is 
diagnosed with a thyroid carcinoma causing hyperthyroidism (Bezzola, 2002). However, not 
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all dogs show signs of hyperthyroidism even though they have a high concentration of thyroxine 
in the blood. (Carver et al., 1995; Fukui et al., 2015). Rijnberk (1971), see Leav et al. (1976), 
studied 57 dogs with thyroid carcinomas, 13 of these also had hyperthyroidism with symptoms 
similar to the ones mentioned above; polyuria, polydipsia, weight loss despite increased 
appetite, restlessness, tachycardia and heat intolerance.  
The hypothesis of thyroid carcinoma causing hyperthyroidism is uncontrollable tumor 
production of T3 and T4. TRH and TSH secretion is inhibited because of the high levels of T3 
and T4 in the blood, making the contralateral normal thyroid gland regress. After surgical 
removal of the thyroid carcinoma, the symptoms of hyperthyroidism disappear (Rijnberk 1971: 
see Leav et al., 1976) 
In a study by Benjamin et al. (1996) beagles with hypothyroidism and lymphocytic thyroiditis 
were examined postmortem. A significant correlation between the hypothyroid dogs and 
thyroid neoplasms was found. The clinical signs consisted of weight gain, obesity, lethargy, 
epidermal scale, hyperpigmentation, and bilateral symmetrical alopecia.  
The hypothesis of the linked hypothyroidism and thyroid neoplasia is that the low blood 
concentration of T3 and T4, which persists during hypothyroidism, causes overstimulation of 
the adenohypophysis and an excess production of TSH. TSH then promotes cell proliferation 
in the thyroid gland, thus leading to increased neoplasia of follicular cells (Benjamin et al., 
1996).  
A case report from 1996 described a dog with hyperthyroidism and a large thyroid carcinoma. 
This dog also presented symptoms consistent with Horner’s syndrome. The authors discussed 
that tumors in the cervical region invading the vago-sympathetic nerve trunk had been 
suggested to cause Horner’s syndrome. They drew the conclusion that thyroid carcinomas 
should be able to do so as well, and could thus be the reason for the symptoms of Horner’s 
syndrome in this dog (Melián et al., 1996).  
Metastasis 
The risk of metastasis seemed to be correlated with the size of the tumor. If the tumor was 1-
20 cm3 the risk of metastasis was 14%, if the tumor was 21-100 cm3 the risk was 74%. A tumor 
with a volume more than 101 cm3 had a 100% chance of metastasis (Leav et al., 1976).  
The lungs, regional lymph nodes and adjacent tissues were the most common site of metastasis 
(Brodey & Kelly, 1968; Leav et al., 1976). 
Diagnosis 
In order to diagnose, classify and stage the thyroid carcinomas clinical examination, 
radiography of the thorax, endoscopy and radio-isotope scanning must be performed. There 
must also be histological examination (Owen, 1980). 
According to a study which compared ultrasound, MRI (magnetic resonance imaging) and CT 
(computed tomography) regarding sensitivity and specificity, MRI was the most sensitive 
(93%) method for detecting thyroid carcinomas compared to CT, with a sensitivity of 85%. 
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However, CT was a more specific (100%) method, compared to MRI, with a specificity of 67% 
(Taeymans et al., 2013). 
At the University animal hospital in Uppsala (UDS), blood samples, ultrasound with/without 
FNA biopsy, CT followed by thyroidectomy is the most common approach when diagnosing a 
thyroid carcinoma. After surgery the removed thyroid is usually sent for a histological 
examination, which confirms the diagnosis and determines classification of the carcinoma. 
Examination and Blood samples  
A thorough clinical examination should always be performed, followed by blood samples; 
hematology, clinical chemical panel, TSH and T4, to study the values and determine whether 
the thyroid is hyperfunctional, hypofunctional or euthyroid. Sometimes kidney- and liver values 
are also valuable (Nadeau & Kitchell, 2011). 
Ultrasound 
Ultrasound is a common way to examine nodules or swellings in the thyroid region (Tuohy et 
al., 2012). It can assess size, volume, and shape of the neoplasm/thyroid gland as well as 
echogenicity and homogeneity. The larynx, trachea and the common carotid artery are nearby 
structures commonly used as hallmarks (Brömel et al., 2005).  
In addition to the thyroid gland and possible carcinoma, identification of the adjacent lymph 
nodes, blood vessels, the esophagus and trachea can be performed with ultrasound. This way it 
is possible to find signs of metastasis in the lymph nodes, to assess how invasive and 
vascularized (using Doppler technique) -the tumor is and whether it is operable or not. 
Ultrasound can also help in determining where the mass originates, and with a color doppler 
technique it is possible to distinguish veins from arteries. Ultrasound is also helpful when 
guiding a fine needle aspiration from a thyroid neoplasm as they can be extensively 
vascularized. With the assistance of an ultrasound it is possible to avoid the largest vessels. A 
thyroid carcinoma is typically hypoechoic and nonhomogeneous compared to normal thyroid 
tissue (Wisner et al., 1993). 
Ultrasound is a quick and fairly easy examination compared to MRI and CT. No anesthetics are 
necessary, unless the neoplasm is pressing on to the larynx/trachea giving symptoms of dyspnea 
(Wisner et al., 1993; 1998). 
FNA 
In a FNA (fine needle aspiration) biopsy a thin needle and a syringe is used. The needle is 
inserted into the neoplasm and the syringe is used to carefully aspirate cellular material. Excess 
aspiration results in blood dilution of the thyroid cells. If the mass is big, repositioning during 
aspiration may be favorable, as long as no blood vessel is punctured. The content is then 
transferred to a microscopy slide, stained and studied in a microscope. Cellularity, cell-size, 
cell-type and shape, adhesiveness of cells, nuclear and chromosomal features, nucleolar 
abnormalities and mitotic activity are assessed (Thompson et al., 1980).  
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In a study by Thompson et al. (1980) the authors show that FNA can be used to diagnose thyroid 
carcinomas. Menard et al. (1986) show that FNA correctly diagnose the malignant neoplasms 
in 71% of the dogs. They hence suggest to use it as a concluding but not excluding method to 
diagnose malignant tumors. If three FNA biopsies fails to conclude cytological changes, a 
surgical biopsy should be made. The authors also points out that FNA is faster, well tolerated 
by the dogs and cheaper than tissue biopsy. 
As mentioned above, an ultrasound guided FNA can help in avoiding blood vessels and hence 
decrease the risk of bleeding and increases the diagnostic value by avoiding taking a FNA 
containing blood.  
Biopsy 
Because of the rich blood supplement to a thyroid carcinoma, tissue biopsies are not taken in 
the clinic. They are only performed with incision, or after surgical removal of the thyroid, to 
get a definite diagnosis and help the veterinarian in making a post-surgical plan and decide 
further treatment (Carver et al., 1995). 
MR imaging 
Size, volume, surrounding structures, shape and intensity can be assessed with an MRI. 
However, MRI has a better sensitivity and specificity than ultrasound when it comes to 
diagnosing thyroid carcinomas. MRI is also the best method for visualizing capsule disruption 
(Taeymans et al., 2008a; 2013).  
The disadvantages of MR imaging is the need for anesthesia, making it time consuming. The 
technique is also expensive.  
In humans, scientists have found a way to differ between papillary carcinomas and benign 
nodules by using MRI. They have done this by comparing T2 SIR (signal intensity ratio) and 
ADC (apparent diffusion coefficient) values. If the mass has a papillary carcinoma the values 
are lower than if it is a benign nodule (Noda et al., 2015). No studies comparing the most 
common thyroid neoplasms in dogs, follicular carcinoma and follicular adenoma, could be 
found in the literature.  
Scintigraphy 
Scintigraphy is used to examine the thyroid glands, regional lymph nodes and the lungs for size, 
position and abnormal uptake of radionuclides (Mitchell et al., 1979). However, the assessment 
of lung metastasis is limited in scintigraphy compared to x-ray or CT because the metastases 
may not have the same uptake of radionuclides as the original tumor (Silverman et al., 1983; 
Adams et al., 1995; Taeymans et al., 2007). 
Three different radionuclides have been used in scintigraphy; 131I, 123I and 99m-Tc 
pertechnetate. In a case report the authors tried both 123I and 99m-Tc pertechnetate on a dog 
with a thyroid carcinoma. It showed that some parts of the carcinoma was not detected with 
99m-Tc pertechnetetate. They therefore suggested that if scintigraphy with 99m-Tc 
pertechnetate was negative, one with 123I should also be performed (Broome & Donner, 1992). 
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99m-Tc pertechnetate was preferred in the study by Bähre et al. (1988) since it was less 
expensive and more available than 123I. Arnold and Pinsky (1975) came to the same conclusion 
in their study, and added that scintigraphy could be performed sooner if pertechnetate was 
injected (20 minutes) than with 123I (4-24 hours). 
By studying the uptake of the administered radionuclide the technician can distinguish 
functional from non-functional thyroid carcinomas with a scintigraphic examination. In a 
hypothyroid carcinoma, the uptake of the administered radionuclide is less than in normal 
thyroid tissue, usually these carcinomas are of the non-differentiated kind (Espineira et al., 
2007). Not many studies has been performed on dogs with hyperthyroidism and scintigraphy, 
but one case report show that one hyperthyroid dog has an increase in uptake of 99m-Tc 
pertechnetate both in the thyroid tissue and the thyroid carcinoma (Petersen et al., 1989). 
To perform a scintigraphy, the dog needs to lie still for a longer period of time, and so general 
anesthesia or sedation is necessary. 99m-Tc pertechnetate is injected intravenously and the dog 
is placed in ventral position over a large field-of-view gamma camera. The uptake peak in the 
thyroid glands happens after 2-3 hours, although after 20 min up to 1 hour after injection the 
ratio of salivary gland uptake and thyroid gland uptake is closest to one in a healthy dog, which 
is why this is the best time to perform the study (Adams et al., 1997). 
CT 
Taeymans et al., (2008b) performed a study on the normal appearance of the thyroid gland on 
CT. Just as the above imaging techniques CT could assess thyroid size, shape, homogeneity, 
location of thyroid tissue and blood vessels. They came to the conclusion that due to the thyroid 
having a high attenuation value compared to surrounding tissue, CT could also distinguish 
thyroid masses from non-thyroid masses, and be helpful in diagnosing suspected thyroid 
neoplasms. They also thought it could aid in staging of the neoplasm and planning of the 
surgery. After injection of iodine the thyroid gland increased in volume. 
A study in dogs from 2017 show that CT is of help in diagnosing thyroid carcinomas. CT make 
it possible to assess shape, volume, invasiveness to surrounding soft tissue, homogeneity, 
mineralization, intratumoral vasculature, regional lymph node size and distant metastases of the 
thyroid carcinoma (Bertolini et al., 2017).  It is more likely that lung metastases are detected 
with CT compared to plain radiographs (Deitz et al., 2014).  
In a study of human thyroids, CT iss compared to scintigraphy. CT is better at identifying 
retrotracheal- and substernal thyroid tissue. It provides more information when it comes to both 
the primary tumor and the ectopic thyroid tissue. For example the extent of them in relation to 
the other adjacent- or mediastinal structures, invasiveness and blood supply. CT can also detect 
calcified tissue, scintigraphy cannot. Metastases to the lymph nodes are detected with CT - and 
not with scintigraphy (Silverman et al., 1983). 
As the animal needs to lie still in a spinal position, general anesthesia or heavy sedation is 
required. This makes CT more time consuming, more expensive and more risky than ultrasound 
or x-ray (Taeymans et al., 2008b).  
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Treatment and prognosis 
Surgical treatment 
If the tumor is movable, relatively small and not too invasive, it is considered surgically 
operable. In a study by Carver et al (1995) 10 out of 12 dogs with medullary thyroid carcinomas 
are assessed to have surgically operable tumors. None of the dogs has evidence of metastasis 
to the lungs at the point of surgery. Eleven of the 21 dogs with thyroid adenocarcinoma in the 
above referred study, are considered to have a surgically operable tumor. Three of these 
presented with metastasis to the lungs.  
Prior to surgery, hematological testing, biochemical analysis, resting thyroxine concentration 
or TSH-response test, and thoracic x-ray should be performed. (Carver et al., 1995; Tuohy et 
al., 2012).  
An extracapsular technique is used for removal of the thyroid carcinoma, to prevent seeding of 
the tumor cells. It is important that at least one of the parathyroid glands remains, even though 
extensive surgery has to be done to remove the tumor. If either parathyroid glands or their blood 
vessels are invaded by tumor tissue, the healthy parathyroid tissue can be minced into 1 mm 
cubes and implanted into muscle. These dogs will likely need calcium supplement for a few 
weeks after surgery. If the parathyroid glands are removed the dog will be hypocalcemic and 
need oral calcium gluconate and vitamin D for the rest of its life (Fukui et al., 2015).  
If the thyroid carcinoma is not removed with clean margins, radiation therapy is recommended 
post-operatively (Fukui et al., 2015). 
Complications may include hemorrhage, seroma, transient hypocalcemia, hypothyroidism, 
temporary upper airway obstruction, aspiration pneumonia and damage to the laryngeal nerve 
(Nadeau & Kitchell, 2011; Tuohy et al., 2012).  
Prognosis after surgery is not good in a study by Carver et al. (1995). A few of the dogs lived 
for at least 12 months after surgery (both dogs with medullary carcinoma and adenocarcinoma), 
but so did the dogs with tumors which did not have surgery. In the study by Fukui et al. (2015) 
the mean survival time is 30 months after surgery, however, the study only includes 6 dogs. 
Tuohy et al. (2012) show a mean survival time of 38.3 months after surgery, in a study on 
fifteen dogs. No recurrence is found at follow up in any of the studies.  
Campos et al. (2014) show that size, volume, histologic type and the amount of expressed Ki-
67 is associated with a macroscopically invasive tumor and a more negative prognosis. Size, 
volume, tumor localization and bilateral vs unilateral tumor is associated with patients having 
distant metastasis, and hence a less favorable diagnosis. Tumor diameter, localization, unilateral 
vs bilateral tumor, ectopic thyroid tissue and tumor mobility is correlated to histological 
invasion. They also show that there is no significant difference in survival after surgery between 




Radiotherapy with 131I 
In a study by Simpson (1975) seven human patients received therapeutic doses of 131I, three of 
these were cured and no recurrence could be shown at check-up 12 years later (patient no 1) or 
17 years later (patient no 2). One patient died of other causes 3.5 years later, without clinical 
signs of recurrence. Three other patients had a relief of symptoms and lived several years after 
treatment, but were not cured of the disease. The last patient did not respond to treatment, 
neither was any sign of 131I uptake by the tumor seen.  
A few studies on animals have been performed. A dog with hyperthyroidism and an inoperable 
thyroid carcinoma was treated with a dose of 2220-2770 MBq 131I on three occasions with an 
interval of 5 to 7 months. However, the symptoms recurred 5 months after the last treatment 
and the dog was euthanized. The authors of the study speculated that dogs with hyperthyroidism 
should be the best candidates in treatment with 131I as their uptake of radionuclides was higher 
than in euthyroid dogs. They also pointed out that treatment of dogs with 131I was problematic 
because of the long hospitalization period due to the need of collecting radioactive feces and 
urine in radiation isolation facilities afterwards (Peterson et al., 1989). 131I may also be used as 
adjunctive treatment to surgery, or alone if the tumor was inoperable because of metastasis 
and/or invasiveness, and if the tumor showed uptake of 131I. In the last case it was considered 
to be prolonging of life rather than curative (Worth et al., 2005).  
In a study by Worth et al. (2005) 32 dogs were given a subcutaneous injection with 131I, another 
group was not treated at all, a third was treated with surgery alone and the fourth was both 
surgically treated and given 131I. The group with the longest mean survival time (34 months) 
was the one treated both surgically and with 131I. The group treated with surgery alone had a 
mean survival time of 30 months. In a study published in 1995 the authors treated seven dogs 
diagnosed with thyroid carcinomas with a variety of surgery, chemotherapy and 131I 
radiotherapy. The four dogs which received only 131I and thyroid hormones did not have a 
significant reduction in tumor size. The mean survival time for the seven dogs was 25 months 
(Adams et al., 1995).  
As pointed out earlier, metastases may not have the same uptake of radionuclides as the 
hyperfunctional thyroid/thyroid carcinoma, and thus the treatment may not be as effective 
towards metastases as towards the original tumor (Silverman et al., 1983; Adams et al., 1995; 
Taeymans et al., 2007).  
Reported side effects were pancytopenia, bone marrow megakaryocytic, erythroid and myeloid 
hypoplasia, hypothyroidism and diarrhea (Adams et al., 1995; Worth et al., 2005).  
External radiation therapy 
In a study of human thyroid carcinomas, external radiation was used on follicular, papillary, 
medullary and thyroid anaplastic carcinomas. In all tumor types it diminished the amount of 
people who had reoccurrence. The patients with anaplastic tumors were the ones with highest 
recurrence frequency. The author concluded that external radiation may be an effective way of 
treatment in any kind of thyroid carcinoma. It should be used after surgery if there was even 
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slight doubt that some tumor tissue remained, in combination with 131I if the tumor was 
inoperable, or alone for undifferentiated tumors which did not concentrate 131I (Simpson, 1975).  
25 dogs with non-operable thyroid carcinomas participated in a study to evaluate external 
radiation (megavoltage) as a therapy and determine duration of progression free survival. The 
dose given was 12 fractions of 4 Gy/fraction over a period of 4 weeks. In the dogs that had 
metastases the disease progressed even after treatment. However, three years after treatment 
the progression free survival was 72%, indicating that irradiation prolonged life in dogs with 
non-operable thyroid carcinomas (Theon et al., 2000).  Another study published in 2001, 
studied megavoltage radiation therapy in 8 dogs with the same protocol as above. The mean 
survival time was 24.5 months (Pack et al., 2001). Earlier studies agree with these results. 
Brearley et al. (1999), treated 13 dogs with non-operable thyroid carcinomas with external 
radiation and found that their mean survival time was 24 months. They all agreed radiation 
therapy was a good palliative treatment.  
Side effects from radiation has been seen in some dogs; tracheal, esophageal or laryngeal 
mucositis for example. This led to hoarseness, mild dysphagia and cough. Skin fibrosis, 
alopecia and chronic tracheitis creating a dry cough has been shown to be the chronic side 
effects of radiation therapy. Cases of hypothyroidism after treatment have also been described 
(Brearley et al., 1999; Theon et al., 2000; Pack et al., 2001). In one study, 21 dogs were treated 
with megavoltage radiation, 47.6% (10) of them were hypothyroid 1-13 months afterwards. The 
dose received did not seem to be related to the risk of developing hypothyroidism. No risk 
factors were identified, but several of these dogs had both had surgery and chemotherapy 
before/during radiation (Amores-Fuster et al., 2015). 
Chemotherapy  
Chemotherapy is rarely used alone in treatment of thyroid carcinomas, but more often in 
conjunction with another therapy. In the study by Nadeau & Kitchell (2011) one group of dogs 
are only surgically treated (28 dogs), and the other both surgically treated and receiving 
chemotherapy (16 dogs) with one or a combination of carboplatin, doxorubicin and gemcitabin. 
Only one complete remission is seen in a dog who received doxorubicin. The other dogs show 
partial remissions. The median survival time is almost the same between the two groups, 510 
VS 518 days.  
Another study performed in 13 dogs given cisplatin showed a mean survival time of 6.3 months. 
Seven of the thirteen dogs had had previous treatment with surgery or doxorubicin. Only 54% 
of the dogs responded to the chemotherapy. Two of the dogs that had partial remission had 
previously been treated with doxorubicin without any success. The authors speculated that 
cisplatin might be effective even when doxorubicin is not (Fineman et al., 1998). In an earlier 
study published in 1988, 36 dogs were evaluated for survival time after treatment with cisplatin. 
The response rate in this study was much lower than in the one above. Only 19% of the dogs 
responded to treatment. However, two of the dogs in this study with partial regression were 
candidates for surgical removal after chemotherapy (Knapp et al., 1988).  
Side effects noted from cisplatin treatment was vomiting, azotemia, anorexia, hemorrhagic 
diarrhea, thrombocytopenia, granulocytopenia, neutropenia and seizures. (Knapp et al., 1988; 
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Fineman et al., 1998).  In a study by Knapp et al. (1988) two of the 41 treated dogs died. One 
due to seizure and one because of hemorrhagic diarrhea. 
The effect of Toceranib in dogs was studied by London et al. (2011). Ten of the fifteen dogs 
had had previous treatment with surgery, radiation or other chemotherapy. Four of the dogs had 
partial regression, while eight were seen to have stable disease after treatment. Two of the dogs 
with partial remission also had lung metastasis. One and five months respectively after 
treatment with toceranib the lung metastasis had resolved. No data on survival time was 
reported in the study (London et al., 2011).  
Side effects noted after toceranib treatment was diarrhea, anorexia, vomiting, musculoskeletal 
pain and/or weakness, weight loss, positive hemocult, lethargy, neutropenia, skin disorder 
(depigmentation) and neutropenia (London et al., 2011). 
Local (inhalation) treatment of lung metastasis with doxorubicin and paclitaxel was evaluated 
in one study. The authors included lung metastases from two thyroid carcinomas but neither of 
these responded to treatment (Hershey et al., 1999).  
Thyroid hormone supplement  
Post-operatively it is common to treat dogs with levothyroxine, especially dogs that have 
undergone extensive thyroidectomy and may develop hypothyroidism. In a study by Fukui et 
al. (2015) the dogs are given levothyroxine post-operatively and thereafter showed normal 
thyroxine concentration.  
Thyroid hormones are not merely given as post-operative treatment but also to suppress the 
endogenous production of TSH and so decrease the risk of making the tumor grow (Simpson, 




MATERIAL AND METHODS 
Literature review 
Data for the literature review was obtained by searching the databases “Web of Science”, 
“PubMed” and “Google Scholar” for scientific articles. The SLU-library service “Primo” was 
also used. Search words were; “Thyroid carcinoma”, “Canine”, “Ectopic thyroid”, “Dog”, 
“Human thyroid carcinoma”, “Staging thyroid carcinoma” “Diagnosis”, “Ultrasound”, “MR 
imaging”, “Computed tomography”, “Scintigraphy”, “Fine-needle aspiration”, “Biopsy”, 
“Treatment”, “Chemotherapy”, “Surgical”, “External radiation” and “131I radiation”.  
Student literature was used for the chapters “Anatomy”, “Physiology” and “Histology” where 
the information was regarded to be common knowledge.  
Collection of data 
A list of 23 dogs treated for thyroid carcinoma at the University Animal Hospital in Uppsala, 
Sweden between years 2008-2018 was created from medical records. Five of the dogs were 
excluded because the medical records lacked data essential to the study (three dogs because 
there was no confirmed diagnosis, and the other two were lacking information concerning time 
of death/euthanasia). To collect missing data concerning date of death/euthanasia or if the dog 
was still alive, 11 owners were first texted and then called. To be included the dogs had to have 
a diagnosis determined by cytology or histology and a date of death, or information on the fact 
that the dog was alive. FNA biopsy indicating thyroid carcinoma was considered enough to 
include the patient in the study.  
All data was collected retrospectively from the medical records (software; Trofast) or animal 
owners. Data collected was: Age at diagnosis, date when the tumor was discovered, date of 
death/euthanasia, breed, sex, type of tumor, suspected metastases, ectopic thyroid tissue or not, 
treated or not, diagnostic methods, side effects of surgery, tumor volume, movability of the 
tumor, performed treatment and time of survival from date of discovery. The tumors were 
divided into two groups depending on high or low malignancy.  
Classification 
The 18 dogs were divided into two groups depending on if they had a confirmed histological 
diagnosis saying follicular thyroid carcinoma. The other group was named “Thyroid carcinoma, 
not further classified”. The dogs were placed in this group if there was any question marks 
concerning the type of thyroid carcinoma, or if the histological diagnosis just said thyroid 
carcinoma. 
Grading 
Survival time was compared for dogs with tumors graded with “low malignancy” and tumors 
graded as “highly malignant”. A highly malignant tumor was a tumor that: broke through the 
connective tissue capsule surrounding the thyroid, had large areas of necrosis, high mitotic 
activity (>5/10 HPF) and/or had metastatic foci. A low malignancy tumor was a tumor that: had 
a low-moderate mitotic activity (<5/10 HPF), lacked large areas of necrosis, had no metastases 
and did not break through the connective tissue capsule surrounding the thyroid. 
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Two of the original 18 dogs in this study were excluded in this particular part of the analysis 
due to lack of data.  
Degree of attachment to underlying tissue 
Sixteen of the dogs were divided into two groups “movable mass” or “not movable mass” based 
on the information in their medical records. Two of the original eighteen dogs were excluded 
from this part of the analysis because of lack of data. The survival time was then compared 
between the two groups. For details, see below the subtitle “treatment”.  
Metastases 
To be included, an examination regarding metastatic status had to be in the records. Three of 
the original 18 dogs were excluded in this particular part of the analysis because of lack of data. 
The 15 dogs were divided into two groups; “metastases” and “no metastases” and survival time 
was then compared. For details, see below the subtitle “treatment”.   
To correlate the volume of the tumor to metastasis, similar to what the scientists in the study by 
Leav et al. (1976) did, the CT-reports in the medical records were scanned for information 
regarding tumor volume. For 11 of the dogs, the volume of the tumor was calculated based on 
the measurements obtained at CT-examination. The other seven dogs were excluded because 
of no CT scan providing a 3D-picture, no/too little information in the medical records regarding 
metastasis, or lack of information in the CT-report.  
Blood analyzes 
For the analysis regarding blood tests the dogs had to have information about TT4, TSH and/or 
calcium levels noted in the journal to be included. If for example, the surgical removal of the 
thyroid carcinoma was performed at another clinic but the follow-up was performed at SLU, 
the test results may have been included in the post-surgical group, but not appear for the same 
dog in the pre-surgery group because of lack of data. 
A Kaplan-Meier analysis was performed based on the information prior to surgery. Fifteen dogs 
were included in the Kaplan Meier analysis for hyperthyroidism VS euthyroidism. See below 
the subtitle “treatment” for details. 
Diagnosis 
Diagnostic methods used to search for metastases were also included in table 6, showing the 
different diagnostic methods used for each patient. Complementary to the diagnostic methods 
brought up in table 6, all dogs went through a thorough clinical examination and had blood tests 
(hematology, CRP, electrolytes) taken, some also had TSH and TT4 tested.  
Most of the biopsies were taken and sent post-operatively. Only two were performed before 
surgery. One with the assistance of ultrasound and one with incision. One of them could not 




Table 6. Table overlooking the different diagnostic methods used on the patients with thyroid 
carcinoma. M check = metastasis check, only lnn = only lymphnodes 
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The difference between biopsy and FNAB as a diagnostic tool was analyzed using Fisher’s 
exact test.  
Treatment 
The dogs were divided into three groups depending on whether they received no treatment, only 
surgical treatment or surgical treatment and chemotherapy.  
Survival times were calculated, and rounded off to the nearest month. Entry date was defined 
by the date when the thyroid carcinoma was discovered as a lump in the throat region, no matter 
the treatment. Although, only dogs treated for thyroid carcinomas after 2008-09-06 were 




All survival distributions in this study were analyzed with the non-parametrical Kaplan Meier-
method. P-values and mean survival time were calculated using the log-rank test. The 
calculations were performed in Excel and MedCalc. The symbols in the graphs (circles, 
triangles and squares) without a following vertical drop is censored data. Censored data is data 






Breed distribution of the dogs included in the study is shown in table 7.  
Table 7. Number and breed distribution of the dogs in this study (a), with consideration of the 
number of dogs registered in Sweden (b) (Jordbruksverket, 2017-12-31). The calculated ratio 
is also shown. 
Breed distribution No of dogs  % of study 
(a) 




Mixed breed  3  17%  27,05%  0,62 
Golden retriever 2  11%  2,68%  4,15 
Alaskan Husky 1  6%  0,07%  74,70 
Am. Staffordshire terrier 1  6%  0,94%  5,90 
Border collie 1  6%  1,31%  4,24 
Labrador retriever 1  6%  3,15%  1,77 
Papillon 1  6%  0,75%  7,44 
Stabyhoun 1  6%  0,08%  70,86 
Siberian husky 1  6%  0,57%  9,68 
Poodle 1  6%  0,55%  10,07 
Tibetan spaniel 1  6%  0,41%  13,45 
Nova Scotia Duck Tolling 
Retriever 
1  6%  0,46%  12,11 
Weimaranier shorthaired 1  6%  0,08%  70,08 
West Highland White Terrier 1  6%  0,34%  16,28 
Whippet 1  6%  0,40%  13,89 







 Sex and Age 
Sex and age of the participating dogs are shown in table 8.  
Table 8. Number and percentage of each sex of dogs participating in the study 
Sex distribution Number of 
dogs 
% of dogs 
Female 6 33% 
Male 7 39% 
Neutered female 3 17% 






No statistical significant difference between male/female, nor amongst neutered females/males 
were found.  
Age distribution of the dogs in the study is shown in figure 2.  
 
Figure 2. A diagram showing the age of the dogs participating in the study, at the time of diagnosis.  
Thyroid carcinoma was most common in older dogs. In this study the mean age of the dogs at 
diagnosis was 9.28 years and the median age was 9.5 years (range 6-13).    
Classification 
Ten of the dogs included in the study were diagnosed with follicular thyroid carcinoma. Eight 
of the dogs had carcinomas which were not further classified.  
Grading 
Based on the information in the medical records the tumors were divided into “highly malignant 
tumor” and “low malignant tumor”. A survival analysis, shown in figure 3, was made to 
compare survival time between the two groups.  
 
Figure 3. Kaplan Meier curve showing the survival time of dogs with highly malignant tumors 



























































The mean survival time of dogs with a grade 2 tumor was 37 months. The mean survival time 
of dogs with a grade 1 tumor was 39 months.  
Clinical signs, Metastases and Ectopic thyroid tissue 
All dogs examined for thyroid carcinoma at The Veterinary Animal Hospital, UDS had a 
swelling in the ventral throat region (18 dogs). Other clinical signs reported was PU/PD (2 
dogs), increased appetite (2 dogs), weight loss (2 dogs), cough (1 dog) and dysphagia (1 dog).  
Based on ultrasound or/and CT-scan, three of the 18 dogs were suspected to have metastases in 
the right retropharyngeal lymph node. No metastases to the lungs could be detected in any of 
the dogs.  
Survival time dependent on attachment to underlying tissue 
A survival analysis (shown in figure 4) was performed to compare survival time depending on 
how attached the tumor was to underlying tissue. 
 
Figure 4. Survival distribution showing the difference in survival time for dogs with tumors that 
at the time for examination was assessed as movable (10 dogs) VS not movable (4 dogs).  No 
significant P-value was obtained (P = 0.9798) 
The mean survival time of dogs with movable tumors was 23 months, and for the dogs with 
unmovable tumors 17 months. 
To investigate whether the movability of the tumor correlated with grade of tumor the data was 
incorporated in table 9.   
Table 9. Distribution of dogs having a grade 2 tumor correlated with clinical movability 
Grade 2 + Movable 8 
Grade 2 + Not movable 4 
Grade 1 + Movable 2 





































Survival time was compared between dogs with metastases and those without. The result was 
shown in figure 5.  
 
Figure 5. A Kaplan Meier curve showing survival time depending on whether metastases were 
evident (3 dogs) or not evident (12 dogs). However, the P-value showed no statistical 
significance. (P=0.9820) 
The mean survival time of dogs without metastases was 34 months, while the mean survival 
time for dogs with metastases was 18 months.   
Tumor volume and correlation to metastasis 
Tumor volume was divided into the same range as in the study by Leav et al. (1976) to 
investigate correlation to metastasis. The result is shown in table 10. 
Table 10. The volume of the tumor was divided into the same range as in the study by Leav et 
al. (1976) 
Tumor volume Number of tumors Metastasis 
1-20 cm3 1 Not known 
21-100 cm3 10 Yes, 3 cases 
>100 cm3 0 0 
The chance of metastasis in dogs with a tumor of 21-100 cm3 in this study was approximately 
33%.  
Ectopic thyroid carcinomas 
Ectopic thyroid carcinoma was suspected in two of the dogs as their tumors showed 
involvement of the hyoid bone. None of these two were autopsied, or had a definite diagnosis 



































Figure 6. Survival distribution comparing dogs with detected ectopic thyroid carcinomas (2) to 
dogs with no detected ectopic thyroid carcinoma (16). P-value = 0.0245. 
The mean survival time of dogs with no detected ectopic thyroid tissue was 36 months. The 
mean survival time of dogs with detected ectopic thyroid tissue was 12 months. 
Blood analyzes 
Pre-treatment 
Six of the 15 tested dogs were hyperthyroid before treatment. The remaining nine dogs were 
euthyroid. Calcium levels were normal in all 10 dogs tested prior to treatment.  
Post-treatment 
After treatment test results showed that four dogs had become hypothyroid due to the surgery. 
Three of these were hyperthyroid prior to surgery. The other two tested dogs were euthyroid. 
All 10 dogs tested for calcium post-treatment had normal values. 
In figure 7 survival distribution comparing functional thyroid carcinomas and euthyroid dogs 
with thyroid carcinoma is presented.  
 
Figure 7. Difference 
in survival time 
between the groups; 
hyperthyroid dogs (6) 
vs euthyroid dogs (9). 
P-value = 0.8736 







































































The mean survival time of hyperthyroid dogs was 38 months. For euthyroid dogs the mean 
survival time was 33 months. 
Diagnosis 
FNA iss compared with biopsy to determine the most successful way to diagnose thyroid 
carcinomas. The data distribution is shown in table 11.  
Table 11. The use of FNA vs Biopsy as a diagnostic method  
 
Diagnostic Not diagnostic 
FNA 4 8 
Biopsy 14 0 
The P-value was calculated using Fisher’s exact test. There was a significant difference at P 
<0.05. Thus, in comparison with FNA, biopsy was more likely to be diagnostic.  
Treatment  
Nine of the dogs were only treated surgically with thyroidectomy. One of these nine dogs had 
partial thyroidectomy of both thyroid lobes. Four other dogs were treated with both 
thyroidectomy and chemotherapy (three with carboplatin and one with toceranib phosphate). 
The remaining five dogs included in the study did not have any treatment of the thyroid 
carcinoma.  
Fourteen of the 18 dogs had tumors which were considered surgically operable. The remaining 
four were too large and/or too invasive.  
Hypothyroidism (4 dogs) and seroma (1 dog) were reported complications to surgery.  
One of the dogs treated with thyroidectomy and adjunctive chemotherapy was presented with 
an infected wound on the paw after the first carboplatin-treatment. This developed into sepsis 
and treatment with carboplatin was therefore terminated.   
Ten of the dogs who had surgical treatment had unilateral thyroid carcinomas. Five of these 
were left-sided and four were right-sided. The medical record of the tenth dog was lacking 
information about which thyroid lobe the tumor was occupying. One of the 18 dogs had bilateral 
thyroidectomy.  
Three of the dogs were treated with levothyroxine post-surgery. One of them was euthanized 
in 2014 and was on medication until then. The other two are still alive, and on medication. 
Survival time in months is compared between the three groups “not treated”, “surgery and 





Figure 8. A Kaplan Meier curve showing the correlation between survival time and treatment method. 
Surgically treated: 9 dogs, not treated: 5 dogs, treated both with chemotherapy and surgery: 4 dogs. 
Survival is measured from the day of diagnosis.  
Neither of the groups had a statistically significant difference in survival time. See table 12.  
Table 12. Table showing groups compared and the P-value obtained by a log-rank test 
Groups compared P-Value 
Surgically treated VS Not treated 0,1135 
Surgically treated VS Treated both with surgery 
and chemotherapy 
0,8118 
Treated both with surgery and chemotherapy VS 
Not treated  
0,4756 
 
The mean survival time of dogs treated surgically was 40 months, while the dogs treated with 
both surgery and chemotherapy had a mean survival time of 29 months. The dogs not treated 
had a mean survival time of 17 months. 
Six of the 18 dogs were euthanized because of their thyroid carcinoma. Four of these dogs did 
not have any treatment.  
Survival 
At the end of the study, 9 dogs were still alive and according to their owners, had no signs of 








































Thyroid carcinoma is an important diagnosis. It is not the most common neoplasm among dogs, 
but it is malignant and more common than the benign thyroid neoplasm, thyroid adenoma. 
(Wurcherer and Wilkes, 2010). Thyroid adenomas are smaller and the dogs usually do not show 
any clinical symptoms because of them. In the study by Leav et al. (1976) adenomas are found 
post-mortem in 30% of the dogs with a thyroid neoplasia, only seven of these are big enough 
to be noticed clinically. Hence, it is not difficult to make the assumption that thyroid adenomas 
are rarely found and diagnosed.  
In humans, medullary thyroid carcinoma has a genetic form. This was explored in a family of 
dogs which seemed to inherit the disease. The scientists could not find the same mutation 
involved in the neoplasm in humans, but the family tree clearly showed the trait was inherited 
(Lee et al., 2006). To know for sure more studies would need to be done to find the mutation 
causing the neoplasm in dogs. Maybe this would be a step closer to find out at least part of the 
etiology.  
Limitations to the study 
This is a retrospective study with a small study population, due to the fact that thyroid 
carcinomas are relatively uncommon. Like all retrospective studies it depends on the medical 
records to be correct. Another factor of uncertainty is that many of these dogs lived and died 
years ago. Even though the owners remember much, specific dates are difficult to recall.  
Dogs with both follicular thyroid carcinomas and not further classified thyroid carcinomas are 
included in the same survival distribution calculations. This may cause a source of error as there 
can be multiple kinds of thyroid carcinomas in the group “not further classified”. The optimal 
situation would is if there had been enough dogs to make one survival analysis for dogs with 
“follicular thyroid carcinomas” and one for “not further classified thyroid carcinomas” but in 
this case the study population is too small.  
Also, there is no data to compare mean survival time of healthy individuals of the same breeds 
at the time of writing. This makes it difficult to say that the dogs did not die of old age.  
Breed, sex and age 
The literature mentions Boxer, Golden retriever and Beagle as overrepresented breeds to 
receive the diagnosis thyroid carcinoma (Brodery & Kelly, 1968; Leav et al., 1976; Wurcherer 
& Wilkes, 2010). In this study the most common breed is mixed breed (3/18) and Golden 
retriever (2/18). The rest of the affected dogs are one breed each, therefore when comparing 
with Sweden’s dog population in total, the most uncommon breeds shows to be predisposed. 
These breeds are not considered to be more likely to be diagnosed with a thyroid carcinoma, 
but rather to be a result of statistical fluctuation.  
In accordance to previous studies, no predilection for gender was found, nor amongst neutered 
dogs, if taking into consideration that every fifth dog in Sweden is neutered (Svenska 
kennelklubben, 2012).  
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Thyroid carcinomas is shown to be more common in older dogs with a mean age of about 10 
years (Brodery & Kelly, 1968; Leav et al., 1976). This is true also for the current study. The 
mean age is 9.28 years and the median age is 9.5 years. The fact that older dogs are more 
commonly affected, contradict that thyroid carcinomas in dogs have the same etiology as 
thyroid carcinomas in young humans exposed to radiation. Studies in young dogs and the effect 
of high radiation doses can not be found though, probably due to ethical reasons of performing 
such a study. Tumor development in the thyroid at an older age may rather imply errors in cell 
division as an etiology, but no articles could be found to support this.  
Sometimes it may be difficult to determine the reason for euthanasia in an old dog, especially 
when reading a study. Even though the study may be about thyroid carcinomas, the dog could 
have another disease not linked to the neoplastic thyroid and die of other causes not known to 
the author. Six of the 18 dogs in this current study are euthanized because of the thyroid 
carcinoma, three due to other causes. The remaining nine dogs are still alive.  
Classification and grading 
According to Lee et al. (2006) and Carver et al. (1995) immunohistochemistry needs to be done 
to distinguish a medullary thyroid carcinoma from a compact follicular thyroid carcinoma. This 
gives reason to believe that medullary carcinomas may be more common than we think. There 
is no information in the journals studied for this paper saying that UDSs lab, “Klinisk kemi” 
use immunohistochemistry to distinguish medullary carcinomas from the follicular thyroid 
carcinomas. Thus, we cannot be sure that there is no medullary thyroid carcinomas amongst the 
dogs diagnosed with follicular thyroid carcinoma.  
The TNM-system is usually used to grade the thyroid tumors in the literature. However, at UDS 
it is not routine procedure to classify the thyroid carcinomas according to TNM. Therefore, to 
get an overview of how malignant the tumors in this study are, the information in the medical 
records is used to grade the tumors into two groups, one with low malignant thyroid tumors and 
one with highly malignant tumors. Most tumors are grouped together in the second group with 
highly malignant tumors. This is concurrent with earlier studies concluding that thyroid 
carcinomas are likely to invade nearby tissue and anatomic structures, grow fast and commonly 
metastasize.  
When analyzing the survival rate using the Kaplan-Meier method the group with a grade 1 
tumor actually lived for a shorter time than the dogs with a grade 2 tumor. This is probably due 
to source of errors, such as a too small number of dogs in the group “Grade 1 tumor”. Looking 
individually at these two dogs the prognosis looks fairly good. The dog with a grade 1 tumor 
and a survival time of 39 months is not euthanized because of the thyroid tumor. According to 
the owner of this dog the thyroid carcinoma did not reappear after surgery. The second dog with 
a grade 1 tumor is still alive 13 months after surgery with no signs of recurrence. No significant 




Clinical signs, Metastases and Ectopic thyroid tissue 
Clinical signs 
The most commonly noted clinical feature described in the literature is a swelling in the ventral 
throat region. All the patients treated at UDS had this symptom, although in most of them this 
was the only symptom. The literature also describes dyspnea, coughing and dysphonia to be 
relatively common symptoms. This difference might be explained by the fact that most of the 
dogs participating in the previous studies had a progressed thyroid carcinoma. Several of the 
studies were performed on dogs which had been through several treatments already, and where 
the treatment, subject to the study was the last option left. At UDS the dogs may have been 
referred from another animal hospital, but rarely unsuccessfully treated previously, and thus the 
tumor could be assumed to not be as progressed as the ones in the previous studies.  
Another explanation could be that in Sweden, due to cultural differences, dog owners might be 
more prone to consult the veterinarian early and get their dog examined for a lump, than in 
other countries.  
Movability of the mass 
The Kaplan Meier analysis in this dissertation show that the survival time for the dogs with an 
unmovable tumor is shorter than for the dogs with a movable tumor. It should however be noted 
that the P-value is high and the result therefore not conclusive. Previous studies on this cannot 
be found. To explore this further, studies with a bigger study population needs to be done.  
The study by Deitz et al. (2014) saying clinical movability cannot be seen to correlate with the 
degree of malignancy or invasion into surrounding tissue, agree with this current study.  Both 
are small studies which limit the probative, but as the dogs with a grade 2 tumor has double the 
amount movable tumors than not movable tumors it seems likely that clinical movability has 
little to do with the invasiveness of the tumor. To assess that, a CT needs to be done.  
Metastases 
The survival distribution of dogs in this study with metastases VS dogs without metastases 
shows a longer survival time for dogs without metastases. As metastasis of the tumor is a well-
known factor for a less favorable prognosis this is not surprising. Although, the difference is 
not statistically significant.  
All tumors in this current study have the volume of 1-20 cm3 or 21-100 cm3. According to Leav 
et al. (1976) the volume of the tumor correlates with the risk of metastasis. Tumors with a 
volume higher than 100 cm3 have a 100% risk of metastasis, while tumors between 21-100 cm3 
have 74% risk. The calculated risk in the current study, is as low as 33% when the tumor is 
between 21-100 cm3. However, two of the three tumors with metastases are in the top three 
tumors with largest volume.  
Ectopic thyroid tissue 
Ectopic thyroid tissue could be found along the cervical region, adjacent to the aorta and/or 
along the hyoid apparatus (Konig & Liebich, 2014; Swartz et al., 1911). Two of the dogs 
participating in this study had an ectopic thyroid carcinoma invading the hyoid bone. This was 
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diagnosed by FNAB, ultrasound and CT, however, no post-mortem examination or histology 
was performed to confirm the diagnosis. The current study showed FNA was a fairly limited 
tool when it came to diagnosing thyroid carcinomas, this uncertainty should be kept in mind 
when interpreting the results. 
When the groups “Dogs with ectopic thyroid carcinoma” and “Dogs with no detected ectopic 
thyroid carcinoma” was compared, a statistical significant difference was obtained in survival 
time. This meant that dogs with an ectopic thyroid carcinoma in the hyoid region had a worse 
prognosis than a dog with a thyroid carcinoma in the normal anatomic location for the thyroid. 
However, these two cases had very invasive types of tumors, both were invading the hyoid 
bone, and one was also invading the linguofacial vein. Thus, their prognosis was obviously not 
good. As there were only two such tumors, one should still be careful to draw conclusions and 
not say that all dogs with ectopic thyroid tumors had a worse prognosis than a dog with a thyroid 
carcinoma. Especially not since the ectopic thyroid tissue can be located in such a variety of 
anatomic locations.  
Blood analyses 
TSH and T4 values are used to determine if the tumor is functional or not. A low TSH- and 
high T4 value indicates hyperthyroidism, while a high TSH- and a low T4 value indicates 
hypothyroidism. It is important to know before surgery as it has an effect on the metabolism. 
The author considers it important to follow up on TSH and T4 values after surgery as several 
thyroidectomies have led to hypothyroidism (Nadeau & Kitchell, 2011; Tuohy et al., 2012).  
Four dogs in this current study are hyperthyroid prior to surgery, three of them are hypothyroid 
after surgery. This supports the hypothesis of uncontrollable tumor production of T3 and T4, 
with the consequence of a regression in the contralateral thyroid lobe. When removing the 
thyroid lobe containing the tumor, there is almost no tissue left to produce T3 and T4, making 
the dog hypothyroid instead. One of these dogs recovered from the hypothyroidism in time, but 
the other two remained on the same dose of levothyroxine.  
All tested dogs were normal in calcium-levels, indicating that the parathyroid remained after 
surgery. If the parathyroid glands are both invaded by the tumor, Fukui et al. (2015) suggests a 
method where they mince the parathyroid gland into small cubes and then implant them into 
muscles. This seems like a clever way to keep the body’s natural way of regulating calcium as 
long as no tumor cells are left in the body and start to grow. The dog in the study by Fukui et 
al. (2015) with the implanted parathyroid gland needed calcium supplement for 110 days, after 
that it was discontinued. Recurrence was suspected at the last follow up (at 42 months post-
surgery), but not confirmed.  
The survival distribution of euthyroid dogs compared to hyperthyroid dogs (before surgery) 
showed a longer survival time for the euthyroid dogs in this study. This could be due to the 
metabolic stress to which the body is exposed by being hyperthyroid, but most dogs are “cured” 
from the hyperthyroidism after surgery. As noted above, three of the hyperthyroid dogs in this 
study became hypothyroid after surgery. Maybe this abrupt change in hormone concentration 
was tough for the body to adjust to. No previous studies comparing this could be found in the 
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literature, and so it was difficult to draw any conclusions based on these relatively few dogs, 
especially as the P-value was high.  
Diagnosis 
Owen (1980) declared five examinations necessary for the diagnosis of thyroid carcinomas. 
However, the diagnostic methods have developed since then. Today it is more common to use 
ultrasound and CT to diagnose the thyroid carcinomas than x-ray and scintigraphy. CT can in 
theory replace ultrasound, the clinician get more information about the tumor from a CT-scan 
than from an ultrasound, especially if the tumor is of substantial size. However, ultrasound is 
cheaper and faster, and even though most dog owners have their dogs insured, this is not true 
for all cases. Ultrasound is also helpful when taking an FNAB to avoid puncturing a blood 
vessel.  
Scintigraphy is used when the clinician has a suspicion of a functional thyroid carcinoma. At 
UDS the radionuclide 99m-Tc pertechnetate is used. It is more available than the other 
radionuclides, cheaper, and the examination can start after 20 minutes, instead of 4-24 hours as 
in a dog who has been injected with 123I. The only drawback of 99m-Tc pertechnetate seems to 
be the uncertainty of it detecting metastases (Bähre et al., 1988; Arnold & Pinsky, 1975). 
Considering the advantages of 99m-Tc pertechnetate it is logical that it is the most used 
radionuclide at UDS. The dogs in this current study, diagnosed with scintigraphy, are scanned 
with 99m-Tc pertechnetate. None of them are proven to have metastases. This might mean that 
there are none with metastasis, but according to the literature (Silverman et al., 1983; Adams 
et al., 1995; Taeymans et al., 2007) the metastases might not have increased uptake, even 
though the original tumor has, and therefore not show on the scintigraphy. No autopsies were 
performed, which makes it difficult to know for sure.  
It is not common to use MR imaging on the patients with a thyroid carcinoma, despite the fact 
that it is proven to be the best method for visualizing capsule disruption (Taeymans et al., 
2008a; 2013). One reason may be that it is more expensive than CT, but it is also safer for both 
animal and personnel without the exposure of the large dose of radiation by a CT-scan. There 
are descriptions in the literature (human medicine) of MRI being used for guidance of FNA 
biopsies as well, but a few obvious things makes an MRI-guided FNA difficult to perform, such 
as the design of the MRI apparatus. It is not easy to access the patient while going through an 
MR-scan. The systems have developed though, but far from all MRI-systems are possible to 
use for taking biopsies (Weiss et al., 2008).  
Research in human medicine has shown a way to differ between human papillary carcinomas 
and benign nodules with the help of MRI (Noda et al., 2015). No studies are found on dogs 
with thyroid carcinomas regarding this, but it would be interesting to know if this fact is true 
even for dogs with thyroid adenoma/carcinoma. If so, this would be an additional reason to 
explore the use of MRI as a diagnostic tool for suspected thyroid neoplasms instead of CT.  
Histological examination was one of Owens (1980) criteria for diagnosing a thyroid carcinoma. 
This still needs to be done to confirm the diagnosis. Many clinicians use FNA biopsy as a first 
step in treatment. Thompson et al. (1980) did research to find out whether FNA could be used 
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in the diagnosis for thyroid carcinomas. They showed that it could, but when looking more 
closely at their results, FNA, in contrast to tissue biopsy and histology, almost never provided 
a definitive diagnosis but rather a step on the way to diagnosis. 
In this current study, biopsy is needed to confirm the diagnosis in most cases, even after a FNA 
biopsy. The author therefore questions FNA biopsy as a tool in the diagnosis of thyroid 
carcinomas. It is an easy method, but can still lead to hemorrhage and discomfort for the dog, 
and is rarely of much use. Furthermore, if this is the only reason for an ultrasound (hence, the 
patient is still going through a CT before surgery) this is one more reason not to do an FNAB 
before surgery. There are articles describing CT-guided FNA biopsies, but these take a long 
time to perform (about 22 minutes) compared to the ultrasound-guided biopsies. However, an 
important positive aspect of the use of an FNAB is that it is useful in ruling out differential 
diagnoses.  
Treatment  
Compared to previous studies (Carver et al., 1995) many of the tumors in this current study 
were operable. In a study by Carver et al. (1995) the percentage of operable tumors was 64%. 
Of the 18 dogs in this study, 78% were considered removable. As noted before, this might be 
due to less progressed tumors in the current study. To support this, three of the dogs with an 
adenocarcinoma had metastasis to the lungs in the study by Carver et al., indicating a more 
progressed neoplasm. 
The dogs studied at UDS had a low frequency of complications during/after surgery compared 
to the dogs in the literature. This may be because their surgeons performing the thyroidectomies 
are well qualified, the tumors were observed early by the owners, the owners were not good at 
reporting the complications, the complications were not incorporated in the journals, or a 
combination of those reasons.  
When comparing survival distribution, the group with dogs treated solemnly with surgery was 
the one with the longest survival time. Mean survival time was calculated to 40 months. Even 
though there was an obvious difference in the group “not treated” and “treated surgically” the 
result of the P-value showed it was not statistically significant. The P-value was however low 
enough to not ignore the results showing the increase in survival time. The mean survival time 
of the dogs not treated was 17 months. More studies on bigger populations needs to be 
performed. However, one should take into consideration that the dogs with thyroid carcinomas 
usually were above middle age. To prolong their life with approximately 40 months was in 
many cases a lot, and maybe all we could ask for. These results are similar to the ones in the 
study by Tuohy et al. (2012) where the mean survival time was 38.3 months. In many aspects 
Tuohy’s study was similar to the current study, the study population was almost the same size 
and the survival time was analyzed using the Kaplan-Meier method. It differs in that Tuohy et 
al. had the groups “dogs treated both surgically and with chemotherapy”, and “dogs treated 
only with surgery” mixed together though.  
The five dogs treated both with surgery and chemotherapy unexpectedly had a lower mean 
survival time than the dogs treated only with surgery. The mean survival time for this group 
34 
 
was 29 months. An explanation could be that the dogs in this group had a worse prognosis even 
from the start, and that may also be the reason for treating them with adjuvant chemotherapy. 
This was partly true, they all had a bad prognosis; one had a very invasive tumor with high 
mitotic activity, one had dirty margins after surgery, one had an anaplastic thyroid carcinoma 
and the last one had infiltrative growth into surrounding tissue. However, so did most of the 
dogs treated only with surgery. Another reason for the bad prognosis could be that the tumor 
was more progressed in these five dogs. The two of these tumors measured at the CT-scan were 
amongst the ones with largest volume. A previous study comparing a group of dogs treated only 
surgically, with a group treated with both chemotherapy and surgery showed almost no 
difference in mean survival time (510 VS 518 days) (Nadeau & Kitchell, 2011). There was a 
study showing a lower survival time, with an average of 191.8 days, but these scientists did not 
differ between dogs who had previous treatment with surgery and dogs that did not. Six of the 
thirteen dogs did not have any previous treatment, which reasonably lowers the survival time. 
The authors of the same study found an interesting fact; two of the dogs who had been 
unresponsive to doxorubicin responded with partial remission when given cisplatin (Fineman 
et al., 1998). The two cytotoxic drugs both bind to the DNA to inhibit the replication. Cisplatin 
had been reported to be a bit less cell cycle specific than Doxorubicin, that fact may play a part 
in why it was more effective on thyroid carcinomas.  
Overall, response to treatment with chemotherapy is low. One study reports 54% (Fineman et 
al., 1998), another 19% (Knapp et al., 1988). This is probably due to that we know too little 
about thyroid carcinomas. Without an etiology it is difficult to find effective treatment as we 
do not know what to direct the treatment at, on a cellular level. Many cytotoxic drugs have 
effect on more than one part of the cell cycle, but since none have been found which seems to 
help substantially, the author of this dissertation thinks there is still much we do not know about 
the upcoming of thyroid carcinomas.  
Four of the five dogs treated at UDS were given carboplatin, and the fifth toceranib. Toceranib 
is a drug inhibiting the enzyme protein kinase. London et al. (2011) studied toceranib given to 
15 dogs with a thyroid carcinoma. Ten of the dogs were previously treated. The study showed 
positive results of treating the dogs with toceranib, and also, it resolved the lung metastases 
evident in two of the dogs. In conclusion; toceranib might be more close to inhibiting the reason 
for the upcoming of thyroid carcinomas than carboplatin or doxorubicin. At the very least, it 
could have a better effect on the metastases of these neoplasms.  
Campos et al. (2014) showed that there was no significant difference in survival between a dog 
with medullary thyroid carcinoma and a dog with follicular thyroid carcinoma. As previously 
noted, these two types of thyroid carcinomas are easy to mistake for each other. Therefore if 
one is only interested in survival time, maybe it is not essential to differ them.  
Radiotherapy with 131I may work if the tumor is hyperfunctional and shows an increased uptake 
of 131I (Peterson et al., 1989). Not many studies are performed on dogs, but one indicates that 
radiotherapy is a good adjunctive treatment to surgery. The dogs treated with both 131I and 
surgery has the longest mean survival time (4 months longer than the group treated only with 
surgery) (Worth et al., 2005).  On the contrary, a study published in 1995 reported no significant 
reduction in tumor size (Adams et al., 1995).  Only one of the seven dogs in Adams study has 
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a hyperfunctional thyroid. These results indicate that the conclusions Peterson et al. (1989) 
draws in their study may be correct. Peterson et al. (1989) also points out the problem with 
treating a dog with 131I – there is a long period of hospitalization in special radiation safe 
facilities after treatment to collect the radioactive waste (urine, feces). No such facilities exists 
for animals in Sweden, making treatment (especially of large dogs) difficult.  Another problem 
to treatment with 131I is that metastases can have a lower or no uptake of the radionuclide. Thus, 
if the dog has metastatic spread, another treatment method, for example chemotherapy may be 
a better option.  
External radiation therapy is considered a good palliative treatment, but with the presence of 
metastases, evidence shows that the disease progresses even after treatment (Theon et al., 
2000). Both the study by Pack et al. (2001) and Brearley et al. (1999) were small and had few 
dogs with metastases. This explains why both of them has a lower survival time than the dogs 
in the study by Theon et al. Theon et al. (2000) presents a mean survival time of 45 months, a 
lot more than the mean survival time of 24, respectively 24,5 months presented in the other 
studies. Although, in the study by Theon et al. (2000) 14 of the 25 dogs are treated surgically 
before referral for external radiation. To summarize; external radiation alone may increase 
survival time with a few months (mean survival time 24 months, compared to the untreated 
group in this current study with a mean survival time of 17 months). Dogs treated with external 
radiation as adjunctive treatment to surgery may have a longer mean survival time than dogs 
treated only surgically (45 months in the study by Theon et al., compared to the current study 
with a mean survival time of 40 months in dogs treated solemnly with surgery).  
CONCLUSION 
In conclusion, the results in this dissertation cannot confirm the hypothesis that treatment 
increases survival time in dogs with thyroid carcinoma, as no significant difference was found 
between dogs not treated, and the dogs that were treated. However, the P-value was relatively 
low, and so maybe with a bigger study population it could be possible to prove that treatment 
prolongs time of survival.  
The only factor which significantly worsened the prognosis was if the dog had neoplastic 
ectopic thyroid tissue. Although, as previously discussed, this conclusion had a few sources of 
errors.  
Further studies are needed to investigate the following potential prognostic factors; grade of 





Elakartad cancer i sköldkörteln är inte den vanligaste diagnosen bland hundar, endast 1-2% av 
alla hundar som får cancer drabbas av just sköldkörtelcancer. Det är ändå en viktig sjukdom att 
uppmärksamma då den elakartade typen är vanligare än den godartade. Diagnos i tidigt skede 
är viktigt för att hinna operera innan tumören växt in alltför mycket i omkringliggande vävnad 
eller spridit sig till någon annan del av kroppen. Ju större tumören hunnit bli, desto större är 
risken för att den ska ha spridit sig. Resultaten i denna studie visar att ju mer fast tumören sitter 
i omkringliggande vävnad, desto sämre prognos. Detta resultat skulle dock kunna bero på 
slumpen då skillnaden inte är tillräckligt stor för att säga att den är statistiskt signifikant.  
Målet med det här examensarbetet var bland annat att uppmärksamma sköldkörtelcancer hos 
hund, samla in information från tidskrifter för att öka kunskapen om tecken på sjukdomen, för- 
och nackdelar med olika sätt att diagnostisera, behandlingsalternativ och prognos för dem. 
Studien på de 18 hundar som behandlats för sköldkörtelcancer på universitetsdjursjukhuset i 
Uppsala de senaste 10 åren var tänkt att ge en indikation på om behandlingen ökar hundarnas 
livslängd. Enligt överlevnadskurvan (se figur 2 i arbetet) är resultaten positiva. Både gruppen 
där sköldkörteln med cancer i tagits bort, och i gruppen där sköldkörteln tagits bort och hunden 
sedan hade behandlats med cellgifter levde längre än hundarna i gruppen som inte fått någon 
behandling. Gruppen var dock för liten för att dra några slutsatser till en större population, som 
t.ex. alla hundar inom europa med sköldkörtelcancer. Resultatet av borttagandet av sköldkörteln 
berodde dessutom på ett flertal olika faktorer, som hur duktig den opererande veterinären var, 
hur långt gången cancern var och hur gammal hunden var. Det verkade ändå vara så att 
borttagning av tumören var den mest effektiva metoden för att öka överlevnadstiden hos 
hunden. Resultaten gav en konkret grund att stå på när man som veterinär rekommenderade 
behandlingsalternativ till en patient på UDS i Sverige. Det skulle också kunna vara till hjälp vid 
diagnos och val av behandling av vilken hund som helst med elakartad sköldkörtelcancer under 
förutsättning att det inte är den enda källan till information.  
Det finns två huvudsakliga grupper man delar in elakartad sköldkörtelcancer i; gruppen där 
tumören utvecklas från en celltyp (C-celler) som bland annat har hand om kalciumomsättningen 
i kroppen – medullär sköldkörtelcancer, och en typ som utgår ifrån sköldkörtelns epitelceller, 
de som bland annat tillverkar hormonen som till stor del styr vår ämnesomsättning – follikulär 
sköldkörtelcancer. Den follikulära typen är vanligast hos hund. Några studier visar dock att en 
särskild typ av follikulär sköldkörtelcancer är lätt att blanda ihop med medullär och att 
mörkertalet därför är stort. Vissa av de follikulära sköldkörteltumörerna producerar för mycket 
av dessa hormoner, de kallas då funktionella sköldkörteltumörer. Resultaten i den pågående 
studien visar att hundarna med en överfunktionell sköldkörteltumör har en sämre prognos än 
en hund med en sköldkörtel som trots sin tumör, fungerar normalt.   
 Den medullära typen är hos människa associerad med en ökad frisläppning av hormonet 
calcitonin, som reglerar kalciumnivåerna i blodet. Trots detta verkar inte kalciumnivåerna 
påverkas hos människa, det har dem dock visats göra hos hund. Hos människa finns också en 
ärftlig variant av medullär sköldkörtelcancer. Lee et al (2006) rapporterar om en familj av 
hundar som uppvisar liknande sjukdomsbild som denna typ. Däremot saknas en av 
mutationerna som ses hos människa med den typen av medullär sköldkörtelcancer.  
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Gradering av sköldkörtelcancer förekommer. Det vanligaste använda systemet är TNM 
(tumour, nodes, metastases). Där används siffror för att tala om hur stor tumören är, om den har 
spridit sig till närliggande lymfknuta/lymfknutor och om metastaser har hittats eller inte. I denna 
studie visade sig överlevnadstiden vara kortare om hunden hade en metastas. På 
universitetsdjursjukhuset i Uppsala är det inte rutin att gradera sköldkörtelcancern efter TNM-
systemet. Inför denna studie delades därför tumörerna upp i grad 1 och grad 2, baserat på 
informationen i journalerna. Överlevnadstiden för hundarna med grad 1 var lägre, men gruppen 
bestod bara av två hundar, varav en lever och en avlivades på grund av andra orsaker än 
sköldkörtelcancern, resultatet bör därför tas med en nypa salt då det var såpass få hundar i 
gruppen.  
Det är inte helt klarlagt hur sköldkörtelcancer hos hund uppstår. På människa är det visat att en 
hög dos strålning i ung ålder ger upphov till sköldkörtelcancer, men något liknande har inte 
bevisats hos hund. Teorier finns om att det har med ett hormon som heter TSH (Thyroid 
stimulating hormone) att göra eftersom det binder till epitelcellerna i sköldkörtel och aktiverar 
dem. Inom humanmedicin har det även gjorts studier på cellnivå och konstaterats olika 
förändringar i cellens beteende och uttryck beroende på typ av sköldkörteltumör.  
Litteraturen anger att sköldkörtelcancer är vanligare hos vissa hundraser; golden retriever, 
boxer och beagle är tre av dessa. På grund av att denna studie innehåller så få patienter kan 
ingen pålitlig slutsats dras baserat på de raserna. Ingen studie bland de som hittats under 
litteratursökningen har kunnat visa att sköldkörtelcancer hos hund är vanligare hos något av 
könen. Även i denna studie, trots de få patienterna, är det ungefär lika många av varje kön. Det 
är i regel äldre hundar över 10 år som får sköldkörtelcancer, vilket även stämmer bra med 
resultaten i denna studie.  
Det allra vanligaste tecknet på att din hund fått sköldkörtelcancer är en knöl på undersidan av 
halsen. Ibland kan de också få svårt att svälja och/eller andas. Hos veterinären tas inledningsvis 
oftast ett prov från sköldkörteln med en tunn nål som sticks in i knölen. Ibland använder man 
ultraljud för att guida nålen rätt, eftersom tumören kan vara mycket blodförsörjd och därmed 
lätt börja blöda. Från det provet kan man ibland sedan hitta tumörcellerna när man tittar på det 
i mikroskop. Pågående studie visar dock att denna metod (finnålsaspiration) är mycket osäker 
i jämförelse med att göra en undersökning på den tumöromvandlade vävnaden efter att den 
blivit borttagen, ett så kallat vävnadsprov. Däremot kan ett FNA vara bra att ta för att utesluta 
att knölen är något annat än en sköldkörteltumör. 
Oftast görs också en så kallad datortomografi på halsen, en slags röntgenteknik där man får ut 
flera röntgenbilder i en lång sekvens, för att kunna studera tumören i flera lager. På så sätt kan 
man se om den går att operera, eller om den någonstans växt in för mycket i omkringliggande 
vävnad/strukturer. Har tumören växt in för mycket i den omkringliggande vävnaden 
rekommenderas inte operation, utan hunden får leva så länge den mår bra och inte störs av 
knölen. Man kan behandla för att förlänga livstiden, med tillexempel radioaktiv strålning som 
har visat sig tillfälligt minska tumörens storlek.  
Om tumören är möjlig att ta bort rekommenderas oftast det, med reservation för att prognosen 
är osäker. Man kan också välja att behandla med cellgifter efter operationen för att få bort 
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eventuella rester av tumören. Enligt resultaten i den här studien ökar inte det överlevnadstiden, 
men det finns studier som visar på en längre överlevnadstid vid operation följt av 
cellgiftsbehandling.  
Studien utfördes genom att göra en sökning i journalsystemet Trofast efter journaler på alla 
hundar som fått diagnosen sköldkörtelcancer på universitetsdjursjukhuset i Uppsala 20080906-
20180906. Journalerna gicks sedan igenom och data från dem samlades in. Några djurägare 
kontaktades via telefon för att samla in kompletterande information. Litteratursökningen 
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